Evidence-informed medical pharmacology article updated 10 November 2026. For education; prescribing requires current local labeling and individual patient assessment.
Overview
Ezetimibe is a nonstatin LDL-cholesterol-lowering agent that blocks intestinal cholesterol uptake. It can be used as an adjunct to statins when LDL-C goals are not achieved, and as an alternative or component of treatment when statins are not tolerated. Its cardiovascular benefit is best established in evidence-based combination regimens and should be distinguished from a claim that monotherapy has identical outcome evidence [1–3].
Molecular mechanism
Ezetimibe selectively inhibits the Niemann–Pick C1-Like 1 (NPC1L1) sterol transporter on the brush border of small-intestinal enterocytes. Less dietary and biliary cholesterol reaches the liver; hepatic LDL-receptor expression consequently increases and clearance of circulating LDL particles rises. It does not inhibit HMG-CoA reductase, block pancreatic triglyceride lipases or bind bile acids as a sequestrant [1].
Pharmacokinetics
Ezetimibe is extensively converted in the intestine and liver to an active glucuronide metabolite, and both parent and metabolite undergo enterohepatic cycling. This correction matters because previous descriptions of ‘absence of significant hepatic metabolism’ were misleading. The total effective elimination half-life is around 22 hours, supporting once-daily dosing; it may be taken with or without food [1].
Dose and LDL response
A common labeled adult dose is 10 mg orally once daily, whether alone or with an appropriate statin. Ezetimibe typically lowers LDL-C by approximately 15–20% as monotherapy and provides additional lowering when combined with a statin; individual response varies. If combined with bile-acid sequestrants, separate administration to reduce impaired ezetimibe exposure, using the timing in the relevant label [1].
Outcome evidence and 2026 dyslipidemia guidance
The IMPROVE-IT trial established modest additional cardiovascular event reduction when ezetimibe was added to simvastatin after acute coronary syndrome. The 2026 ACC/AHA guideline recommends nonstatin add-on treatment, especially ezetimibe and/or PCSK9 monoclonal antibodies, in patients at very high ASCVD risk when maximally tolerated statins fail to reach an LDL-C goal below 55 mg/dL; other goals depend on risk. Ezetimibe is not a substitute for comprehensive cardiovascular risk management [2,3].
Safety, drug interactions and monitoring
Ezetimibe is generally well tolerated; diarrhea, abdominal symptoms, fatigue or myalgia can occur. Review liver tests and myopathy symptoms, particularly when coadministered with statins. Severe hepatic impairment is a major precaution, and moderate/severe hepatic impairment calls for avoidance under product recommendations. Cyclosporine can increase exposure; fibrate combinations require consideration of gallstone and product-specific interaction cautions [1].
Practical conclusion
Use LDL-C response, background statin intensity and absolute cardiovascular risk to guide treatment. Avoid asserting that ezetimibe is metabolically inactive or that LDL lowering from all treatments entails identical proven outcome benefits [1–3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Blumenthal RS, et al. 2026 ACC/AHA multisociety guideline on the management of dyslipidemia. Circulation. 2026;153:e1154–e1276. doi:10.1161/CIR.0000000000001423. Available from: https://doi.org/10.1161/CIR.0000000000001423
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi:10.1056/NEJMoa1410489. Available from: https://doi.org/10.1056/NEJMoa1410489
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.